Chronic myeloid leukemia: The race is yet to be won

Por Cortes, Jorge
Publicado em 2012

Marine biodiversity of Costa Rica, Central America

Por Wehrtmann, Ingo S., Cortés, Jorge
Publicado em 2009

The changing face of acute myeloid leukemia therapeutics in the elderly population

Por Daver, Naval, Cortes, Jorge
Publicado no South Asian J Cancer (2015)

How I treat newly diagnosed chronic phase CML

Por Cortes, Jorge, Kantarjian, Hagop
Publicado no Blood (2012)

Molecular biology of bcr-abl1–positive chronic myeloid leukemia

Por Quintás-Cardama, Alfonso, Cortes, Jorge
Publicado em 2009

Optimizing management of ruxolitinib in patients with myelofibrosis: the need for individualized dosing

Por Mesa, Ruben A, Cortes, Jorge
Publicado no J Hematol Oncol (2013)

Nilotinib for the treatment of chronic myeloid leukemia: An evidence-based review

Por Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Publicado em 2010

Estimations of the Increasing Prevalence and Plateau Prevalence of Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors Therapy

Por Huang, Xuelin, Cortes, Jorge, Kantarjian, Hagop
Publicado em 2012

IS THERE A “STANDARD” INDUCTION REGIMEN FOR PATIENTS WITH ACUTE MYELOID LEUKEMIA?

Por Ravandi, Farhad, Cortes, Jorge, Kantarjian, Hagop
Publicado em 2013

Long-Term Outcomes in the Second-Line Treatment of Chronic Myeloid Leukemia: A Review of Tyrosine Kinase Inhibitors

Por Jabbour, Elias, Cortes, Jorge, Kantarjian, Hagop
Publicado no Cancer (2010)

Omacetaxine: a protein translation inhibitor for treatment of chronic myelogenous leukemia

Por Gandhi, Varsha, Plunkett, William, Cortes, Jorge E.
Publicado em 2014

Suboptimal Response to or Failure of Imatinib Treatment for Chronic Myeloid Leukemia: What Is the Optimal Strategy?

Por Jabbour, Elias, Cortes, Jorge E., Kantarjian, Hagop M.
Publicado em 2009

Development and targeted use of nilotinib in chronic myeloid leukemia

Por Fava, Carmen, Kantarjian, Hagop, Cortes, Jorge, Jabbour, Elias
Publicado em 2009

Homoharringtonine/Omacetaxine Mepesuccinate: The Long and Winding Road to Food and Drug Administration Approval

Por Kantarjian, Hagop M., O’Brien, Susan, Cortes, Jorge
Publicado em 2013

Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

Por Prescott, Hillary, Kantarjian, Hagop, Cortes, Jorge, Ravandi, Farhad
Publicado em 2011

FLT3 Inhibitors in the Treatment of Acute Myeloid Leukemia: The Start of an Era?

Por Pemmaraju, Naveen, Kantarjian, Hagop, Ravandi, Farhad, Cortes, Jorge
Publicado no Cancer (2011)

Monitoring Molecular Response in Chronic Myeloid Leukemia

Por Cortes, Jorge, Quintás-Cardama, Alfonso, Kantarjian, Hagop M.
Publicado no Cancer (2010)

Mutant BCR-ABL clones in chronic myeloid leukemia

Por Mathisen, Michael S., Kantarjian, Hagop M., Cortes, Jorge, Jabbour, Elias
Publicado em 2011

The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia

Por Nazha, Aziz, Romo, Carlos G., Kantarjian, Hagop, Cortes, Jorge
Publicado em 2013

Tyrosine kinase inhibitor–induced platelet dysfunction in patients with chronic myeloid leukemia

Por Quintás-Cardama, Alfonso, Han, Xin, Kantarjian, Hagop, Cortes, Jorge
Publicado em 2009